241 related articles for article (PubMed ID: 12188026)
1. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases.
Adorini L
Int Immunopharmacol; 2002 Jun; 2(7):1017-28. PubMed ID: 12188026
[TBL] [Abstract][Full Text] [Related]
2. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents.
Mathieu C; Adorini L
Trends Mol Med; 2002 Apr; 8(4):174-9. PubMed ID: 11927275
[TBL] [Abstract][Full Text] [Related]
3. Induction of tolerogenic dendritic cells by vitamin D receptor agonists.
Adorini L; Penna G
Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor as a drug discovery target.
Pinette KV; Yee YK; Amegadzie BY; Nagpal S
Mini Rev Med Chem; 2003 May; 3(3):193-204. PubMed ID: 12570835
[TBL] [Abstract][Full Text] [Related]
5. Intervention in autoimmunity: the potential of vitamin D receptor agonists.
Adorini L
Cell Immunol; 2005 Feb; 233(2):115-24. PubMed ID: 15936743
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands.
Adorini L; Penna G; Giarratana N; Roncari A; Amuchastegui S; Daniel KC; Uskokovic M
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):437-41. PubMed ID: 15225816
[TBL] [Abstract][Full Text] [Related]
7. Noncalcemic actions of vitamin D receptor ligands.
Nagpal S; Na S; Rathnachalam R
Endocr Rev; 2005 Aug; 26(5):662-87. PubMed ID: 15798098
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells.
Penna G; Amuchastegui S; Laverny G; Adorini L
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V69-73. PubMed ID: 18290726
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor modulators for inflammation and cancer.
Yee YK; Chintalacharuvu SR; Lu J; Nagpal S
Mini Rev Med Chem; 2005 Aug; 5(8):761-78. PubMed ID: 16101412
[TBL] [Abstract][Full Text] [Related]
10. [Current Topics on Vitamin D. Nonsecosteroidal vitamin D mudulators and prospects for their thepapeutic application].
Makishima M
Clin Calcium; 2015 Mar; 25(3):403-11. PubMed ID: 25716814
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands.
Choi M; Makishima M
Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D endocrine system and psoriasis vulgaris--review of the literature.
Rucević I; Barisić-Drusko V; Glavas-Obrovac L; Stefanić M
Acta Dermatovenerol Croat; 2009; 17(3):187-92. PubMed ID: 19818218
[TBL] [Abstract][Full Text] [Related]
14. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
15. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor ligands for osteoporosis.
Cheskis BJ; Freedman LP; Nagpal S
Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
[TBL] [Abstract][Full Text] [Related]
17. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes.
Adorini L
Ann N Y Acad Sci; 2003 Apr; 987():258-61. PubMed ID: 12727648
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists.
Adorini L; Penna G
Hum Immunol; 2009 May; 70(5):345-52. PubMed ID: 19405173
[TBL] [Abstract][Full Text] [Related]
20. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases.
Adorini L; Penna G; Giarratana N; Uskokovic M
J Cell Biochem; 2003 Feb; 88(2):227-33. PubMed ID: 12520519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
